A combination of the activation marker CD86 and the immune checkpoint marker B and T lymphocyte attenuator (BTLA) indicates a putative permissive activation state of B cell subtypes in healthy blood donors independent of age and sex

BACKGROUND: The use of anti-B cell based therapies in immune-mediated diseases targeting general B cell markers or molecules important for B cell function has increased the clinical needs of monitoring B cell subpopulations. RESULTS: We analyzed the expression profile of cell surface markers CD86 an...

Descripción completa

Detalles Bibliográficos
Autores principales: Axelsson, Susanne, Magnuson, Anders, Lange, Anna, Alshamari, Aseel, Hörnquist, Elisabeth Hultgren, Hultgren, Olof
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082969/
https://www.ncbi.nlm.nih.gov/pubmed/32197584
http://dx.doi.org/10.1186/s12865-020-00343-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082969/
https://www.ncbi.nlm.nih.gov/pubmed/32197584
http://dx.doi.org/10.1186/s12865-020-00343-2

Ejemplares similares